Skip to main content

Benign Prostate Hyperplasia

4
Pipeline Programs
5
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Medifocus
MedifocusMD - Columbia
1 program
1
ProlievePhase 41 trial
Active Trials
NCT02021032Unknown250Est. Aug 2018
Prevail Therapeutics
1 program
1
5 mg TadalafilPhase 3
Ildong Pharmaceutical
1 program
1
TamsulosinPhase 31 trial
Active Trials
NCT02827578Unknown588Est. Dec 2017
Yuyu Pharma
Yuyu PharmaKorea - Seoul
1 program
1
TadalafilPhase 11 trial
Active Trials
NCT02839122Completed28Est. Sep 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MedifocusProlieve
Ildong PharmaceuticalTamsulosin
Yuyu PharmaTadalafil

Clinical Trials (3)

Total enrollment: 866 patients across 3 trials

NCT02021032MedifocusProlieve

Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH)

Start: Feb 2006Est. completion: Aug 2018250 patients
Phase 4Unknown
NCT02827578Ildong PharmaceuticalTamsulosin

Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia

Start: Jan 2016Est. completion: Dec 2017588 patients
Phase 3Unknown
NCT02839122Yuyu PharmaTadalafil

A Study to Investigate the Pharmacokinetic Drug Interactions Between Dutasteride and Tadalafil in Healthy Male Subjects

Start: May 2016Est. completion: Sep 201628 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.